Isoptin SR

This page contains recent news articles, when available, and an overview of Isoptin SR but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

India's Ranbaxy Laboratories to sell Isoptin SR in US  -  Jul 30, 2007
MUMBAI (Thomson Financial) - India's largest pharmaceutical company Ranbaxy Laboratories Ltd said it has started the production and sale of its first ... Forbes

Calcium Channel Blocking Agents (Systemic).  -  Aug 1, 2006
Cardene(6) Cardizem(2) Cardizem CD(2) Cardizem LA(2) Cardizem SR(2) Dilacor-XR(2) DynaCirc(5) Isoptin(9) Isoptin SR(9) Nimotop(8) Norvasc(10) Plendil(3) ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com

Calcium Channel Blocking Agents (Systemic).(Drug overview)  -  May 1, 2006
Cardene(6) Cardizem(2) Cardizem CD(2) Cardizem LA(2) Cardizem SR(2) Dilacor-XR(2) DynaCirc(5) Isoptin(9) Isoptin SR(9) Nimotop(8) Norvasc(10) Plendil(3) ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com

Par Pharmaceutical Reports Sales and Earnings for 2005.  -  Feb 28, 2006
This includes the fourth-quarter charge of $5.8 million, after tax, related to Par's acquisition of the product registration to Isoptin SR. ... Free with registration - PR Newswire - AccessMyLibrary.com

Generic Drugs; Pharma company to market Verapamil Hydrochloride …  -  Mar 1, 2005
Par has also acquired the product registration to Isoptin SR and, under the terms of the ... Par will receive a royalty on FSC's sales of Isoptin SR, ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

Generic Drugs; Pharma company to market Verapamil Hydrochloride …  -  Mar 4, 2005
Par has also acquired the product registration to Isoptin SR and, under the terms of the ... Par will receive a royalty on FSC's sales of Isoptin SR, ... Pay-Per-View - Drug Week - Factiva, from Dow Jones

Finance; Par Pharmaceutical reports total revenues of $433.2 million...  -  Mar 28, 2006
This includes the fourth-quarter charge of $5.8 million, after tax, related to Par's acquisition of the product registration to Isoptin SR. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

Ranbaxy.  -  Aug 13, 2007
..."The commercialization of Isoptin SR heralds Ranbaxy's entry into the authorized generics space," said K. Venkatachalam, vice president and regional ... $9.94 - Drug Store News - Alacra Store

Ranbaxy.  -  Aug 13, 2007
..."The commercialization of Isoptin SR heralds Ranbaxy's entry into the authorized generics space," said K. Venkatachalam, vice president and regional ... $9.94 - Drug Store News - Alacra Store

Competitors by Product Report  -  Aug 2, 2008
Abbott Laboratories (ABT) Products:. Isoptin SR (Verapamil Hydrochloride); KOS Pharmaceuticals Cardizem LA (Diltiazem Hydrochloride) ... $75.00 - Revere - Alacra Store

Competitors by Product Report  -  Aug 2, 2008
Abbott Laboratories (ABT) Products:. Isoptin SR (Verapamil Hydrochloride); KOS Pharmaceuticals Cardizem LA (Diltiazem Hydrochloride) ... $75.00 - Revere Reports - Revere

Competitors by Product Report  -  Mar 29, 2008
Abbott Laboratories (ABT) Products:. Isoptin SR (Verapamil Hydrochloride); KOS Pharmaceuticals Cardizem LA (Diltiazem Hydrochloride) ... $75.00 - Revere Reports - Revere

Antidepressant-induced sweating.(Drug-Drug Interactions)  -  Jul 1, 2005
...dyslipidemia that was treated with atorvastatin (Lipitor) 20 mg daily; hypertension treated with sustained-release verapamil (Calan SR, Isoptin SR) 180 ... Free with registration - Brown University Geriatric Psychopharmac... - AccessMyLibrary.com

BRIEFING - ASIA HEALTH - JULY 31, 2007.  -  Jul 31, 2007
NEW DELHI - Pharmaceutical major Ranbaxy Laboratories (BSE:500359) on MOnday said it has commercialised its first authorised generic product, Isoptin SR ... Free with registration - AsiaPulse News - AccessMyLibrary.com

New generics.(product introduction, drug approvals)  -  Mar 7, 2005
As a generic alternative to Abbott Laboratories' Isoptin SR, Par Pharmaceutical, Spring Valley, NY, (845) 425-7100, is introducing verapamil hydrochloride ... Free with registration - Drug Topics - AccessMyLibrary.com

Competitors by Product Report  -  Oct 4, 2008
Abbott Laboratories (ABT) Products:. Isoptin SR (Verapamil Hydrochloride); KOS Pharmaceuticals Cardizem LA (Diltiazem Hydrochloride) ... $75.00 - Revere - Alacra Store

Adenosine vs. calcium channel blockers for supraventricular tachycardi...  -  Jun 1, 2007
Adenosine and verapamil (Calan, Isoptin SR) are equally effective for treating acute supraventricular tachycardia in adults. Patients treated with adenosine ... Free with registration - American Family Physician - AccessMyLibrary.com

Manufacturers continuing to expand reach.(Special Report)  -  Feb 28, 2005
It has entered into an agreement to market verapamil hydrochloride extended-release tablets, a generic version of Isoptin SR.. ... Pay-Per-View - Chain Drug Review - Factiva, from Dow Jones

Medication advice.(Mail)(Letter to the Editor)  -  Oct 1, 2005
...from the 'slow release' products which are not suitable to be crushed (eg Efexor-XR[R], Isoptin SR[R], Sinemet CR[R] and Tegretol CR[R] respectively). ... $4.95 - Australian Nursing Journal - ECNext

Medication advice.(Mail)(Letter to the Editor) | Article from...  -  Oct 1, 2005
...from the 'slow release' products which are not suitable to be crushed (eg Efexor-XR[R], Isoptin SR[R], Sinemet CR[R] and Tegretol CR[R] respectively). ... Pay-Per-View - Australian Nursing Journal - HighBeam Research

Management of hypertension in older persons.  -  Feb 1, 2005
...in combination with other negative chronotropes, such as diltiazem (Cardizem CD, Dilacor XR, Tiazac), verapamil (Isoptin SR, Calan SR), or digoxin. ... $4.95 - American Family Physician - ECNext

Management of hypertension in older persons.  -  Feb 1, 2005
...in combination with other negative chronotropes, such as diltiazem (Cardizem CD, Dilacor XR, Tiazac), verapamil (Isoptin SR, Calan SR), or digoxin. ... Pay-Per-View - American Family Physician - Factiva, from Dow Jones





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy